NVS Novartis AG
- Official Name: Novartis Inc.
- Headquarters: One Health Plaza, EAST HANOVER, NJ 07936, US
- CEO: Vasant Narasimhan
- Website: novartis.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 1.881 | (1.081) - (2.962) | ||
| 2025-07-21 | 2 | Won by 1.539 | 1.322 - (0.217) | ||
| 2025-07-23 | 1R | Won by 0.032 | 1.492 - 1.460 | ||
| 2025-07-28 | 3 | Won by 0.233 | 4.409 - 4.176 | ||
| 2025-07-29 | 2R | Won by 2.153 | 1.056 - (1.097) | ||
| 2025-08-04 | 4 | Lost by 1.085 | 1.620 - 2.705 | ||
| 2025-08-06 | 2R | Lost by 2.229 | (2.702) - (0.473) | ||
| 2025-08-11 | 5 | Won by 4.176 | 1.403 - (2.773) | ||
| 2025-08-12 | 3R | Lost by 1.791 | 1.255 - 3.046 | ||
| 2025-08-18 | 6 | Lost by 0.482 | 3.972 - 4.454 | ||
| 2025-08-25 | 7 | Won by 7.894 | 4.073 - (3.821) | ||
| 2025-09-01 | 8 | Won by 1.619 | 1.358 - (0.261) | ||
| 2025-09-08 | 9 | Won by 2.939 | 1.855 - (1.084) | ||
| 2025-09-15 | 10 | Lost by 1.066 | (4.596) - (3.530) | ||
| 2025-09-22 | 11 | Lost by 2.642 | 0.042 - 2.684 | ||
| 2025-09-29 | 12 | Won by 1.109 | 0.614 - (0.495) | ||
| 2025-10-06 | 13 | Won by 7.285 TOTW | 5.293 - (1.992) | ||
| 2025-10-13 | 14 | Won by 1.018 | (2.119) - (3.137) | ||
| 2025-10-20 | 15 | Won by 0.200 | 1.947 - 1.747 |
Latest News
Yahoo - 2026-10-14
3 AI Stocks With Revenue Growth Up To 29%
Fresh CPI data shows US inflation at 3.7% in September, with AI data center construction flagged as one of the cost drivers. Rising prices and the pro...
Yahoo - 2026-10-14
Gecina – Business at September 30, 2026
PARIS, October 14, 2026--Regulatory News: Gecina (Paris:GFC):
Yahoo - 2026-10-14
MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
BOSTON, October 14, 2026--MindWalk Holdings Corp. (NASDAQ: HYFT) ("MindWalk" or the "Company"), a Bio-Native AI company, today ann...
Yahoo - 2026-10-14
What Is Novartis (SWX:NOVN) Signaling With Its Dual Hives Approval And MS Data?
Novartis (SWX:NOVN) received FDA approval for Rhapsido (remibrutinib) as a treatment for chronic spontaneous urticaria and symptomatic dermographism w...
Yahoo - 2026-10-14
3 Commodity Stocks Riding China Import Demand In 2026
China’s latest trade report has lit a fire under global commodity stories, with September exports up 36.3% and imports up 31% year on year. That kin...
Yahoo - 2026-10-13
Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?
Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.
Yahoo - 2026-10-13
Soufflé Therapeutics™ Announces Oversubscribed $135 Million Series B Financing to Advance Lead Clinical Programs and Continued Pipeline Progress
BOSTON, October 13, 2026--SOUFFLÉ THERAPEUTICS, INC. ("Soufflé™" or "Company"), a leading RNA therapies company aimed at advan...
Yahoo - 2026-10-13
Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), ann...
Yahoo - 2026-10-13
Gossan Resources Announces Offering of Units for Gross Proceeds of $500,000
Winnipeg, Manitoba--(Newsfile Corp. - October 13, 2026) - Gossan Resources Limited (TSXV: GSS) (FSE: GSR) (XETRA: GSR) (the "Company" or &qu...
Yahoo - 2026-10-13
Melexis: Transparency declaration by Invesco Ltd.
Melexis NV (Euronext Brussels: MELE)Press release – Regulated informationTessenderlo (BE), 13 October 2026 – 07:00 CET Disclosure of transparency ...
Yahoo - 2026-10-12
Oil Price Swings Put SK Innovation Stock And Global Energy Producers In Focus
Energy markets are back in the spotlight as Brent and WTI react to Middle East risk, Russia’s shifting fuel exports and fresh forecasts from Goldman...
Yahoo - 2026-10-12
Two major long-term leases for Gecina’s portfolio in La Défense
PARIS, October 12, 2026--Regulatory News: Gecina (Paris:GFC):
Yahoo - 2026-10-11
SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH
The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.
Show more
Yahoo - 2026-10-10
Why Ramsay Générale de Santé (ENXTPA:GDS) Is Back In The Spotlight
Yahoo - 2026-10-09
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Yahoo - 2026-10-09
Melexis (ENXTBR:MELE) Stock May Be 27% Undervalued As Cash Flow Holds Up
Yahoo - 2026-10-09
Cancer Stocks to Consider as Oncology Innovation Accelerates
Yahoo - 2026-10-09
Suominen’s financial reporting in 2027
Yahoo - 2026-10-08
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
Yahoo - 2026-10-08
Argenx Stock Sinks on Scrapped Autoimmune Drug Trial. Why the Selloff Is Overdone.
Yahoo - 2026-10-08
INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF SEPTEMBER 30, 2026
Yahoo - 2026-10-08
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Yahoo - 2026-10-08
Pheochromocytoma and Paraganglioma (PCPG) Market to Reach US$670 Million by 2036 at 7.3% CAGR, Driven by Targeted and Radioligand Therapies
Yahoo - 2026-10-07
VERBUND AG: Stefan Waldner Appointed Chief Financial Officer
Yahoo - 2026-10-07
Sector Update: Healthcare Stocks Rise Late Afternoon
Yahoo - 2026-10-07
Sector Update: Healthcare Stocks Rise in Afternoon Trading
Benzinga - 2026-10-07
FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives
Yahoo - 2026-10-07
Rivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment
Benzinga - 2026-10-07
Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism
Yahoo - 2026-10-07
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Yahoo - 2026-10-06
Information Regarding the Total Voting Rights and Shares of Gecina as of September 30, 2026 (1)
Yahoo - 2026-10-06
Klépierre: Disclosure of transactions in own shares from September 30 to October 2, 2026
Yahoo - 2026-10-06
RAMSAY SANTE : Final annual results as of 30 June 2026
Yahoo - 2026-10-06
SAP Puts the Autonomous Enterprise to Work
Yahoo - 2026-10-06
Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium
Yahoo - 2026-10-06
Norwegian Air September traffic climbs 7% on strong autumn demand
Yahoo - 2026-10-05
3 Multinational Stocks Retail Investors Are Watching As Trade Risks Rise
Yahoo - 2026-10-05
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Yahoo - 2026-10-05
GE HealthCare Bets $945M on Fast-Growing Market With Sofie Biosciences Acquisition
Yahoo - 2026-10-05
HighCo: SHAREHOLDING
Yahoo - 2026-10-03
NKT (CPSE:NKT) Stock Sees Modest Fair Value Lift After More Balanced Analyst Views
Yahoo - 2026-10-02
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Yahoo - 2026-10-02
Sector Update: Healthcare Stocks Steady Late Afternoon
Yahoo - 2026-10-02
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
Yahoo - 2026-10-02
Novartis licenses Abogen mRNA autoimmune drug in $7.8B deal
Yahoo - 2026-10-02
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Yahoo - 2026-10-02
Novartis Signs RNA Therapy Licensing Deal With China’s Abogen Worth Up to $7.8 Billion
Yahoo - 2026-10-02
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
Yahoo - 2026-10-01
Change in the holding of Suominen’s treasury shares
Yahoo - 2026-10-01
Deutsche Bank lists Top European Stock picks for the next twelve months
Yahoo - 2026-10-01
Suominen Corporation – Manager’s transaction: Charles Héaulmé
SeekingAlpha - 2026-10-01
Top 25 Attractive Dividend Stocks For October 2026
Yahoo - 2026-10-01
Rezolv secures up to $636m for 1.3GWp Dama Solar project in Romania
Yahoo - 2026-09-30
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
SeekingAlpha - 2026-09-30
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario
Yahoo - 2026-09-30
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
Yahoo - 2026-09-29
Schweizer Electronic AG Transitions to the Scale Segment of the Frankfurt Stock Exchange
Yahoo - 2026-09-29
CAS announces collaboration with Novartis to advance AI-ready reaction informatics
Yahoo - 2026-09-29
Hungary’s OTP Bank weighs Russia exit amid Luminor purchase – report
Yahoo - 2026-09-29
European equities edge up as yield spike and rising crude saps sentiment
Yahoo - 2026-09-29
ARTHEx Biotech Announces Appointment of Glenn P. Sblendorio as Chairman of the Board
Yahoo - 2026-09-29
NKT reaffirms strategic direction and presents capital allocation priorities at Investor Day 2026
Yahoo - 2026-09-28
Klépierre (ENXTPA:LI), Why Is The Stock Getting Attention Now?
Yahoo - 2026-09-27
Gecina (ENXTPA:GFC), What Is Drawing Fresh Attention Now?
ChartMill - 2026-09-26
Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile
Yahoo - 2026-09-25
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
Yahoo - 2026-09-24
Novartis (SWX:NOVN) Lands Global Radioligand Therapy License To Deepen Cancer Pipeline
Yahoo - 2026-09-24
Roche targets Novartis on IgAN market after Phase III win
Yahoo - 2026-09-24
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
Yahoo - 2026-09-24
Mercialys Appoints Jérôme Engelbrecht as Group CFO
Yahoo - 2026-09-24
Pharmaceutical Drug Delivery Market Forecasts Growth from $2.15T (2026) to $2.92T by 2031, Profiling J&J, Pfizer, Roche, BD & Novartis
Yahoo - 2026-09-23
Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
Yahoo - 2026-09-23
Creatio commits $300m to scale financial AI
Yahoo - 2026-09-23
Roche, Ionis RNA drug scores in kidney disease study
Yahoo - 2026-09-23
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Yahoo - 2026-09-23
BoomRay and Novartis sign $900m deal for radioligand therapy
Yahoo - 2026-09-22
3 Integrated Oil And Gas Stocks Tied To Iran Supply Risk
Yahoo - 2026-09-22
AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’
Yahoo - 2026-09-22
Creatio Invests $300 Million in Its Bank.AI Platform to Drive AI Adoption in Financial Services
Benzinga - 2026-09-22
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Yahoo - 2026-09-22
Capitalize on the Orphan Drug Revenue Shift: Benchmark Novartis, Roche, Pfizer, Sanofi and AstraZeneca to Secure High-Value Growth Before Rivals Move First
Yahoo - 2026-09-22
BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
Yahoo - 2026-09-21
Morgan Stanley flags Amgen's edge after heart-drug rival stumbles
Yahoo - 2026-09-21
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
Yahoo - 2026-09-21
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations
Yahoo - 2026-09-21
Melexis: update on the share buy-back program
Yahoo - 2026-09-21
Wegovy Maker Novo Looks to New Drugs to Combat Lilly, but Investors Are Unconvinced
Yahoo - 2026-09-19
What does the EU have that the U.S. does not?
Yahoo - 2026-09-19
Edison (BIT:EDNR) Shares Dropped, So What Is Driving Attention Now?
Yahoo - 2026-09-18
Novartis (SWX:NOVN) Takes Full Control Of A Brain Delivery Platform
Yahoo - 2026-09-18
Gossan Resources Announces Changes to Board and Management
Yahoo - 2026-09-18
4 Biotech Stocks to Watch as Potential Takeover Targets
Yahoo - 2026-09-18
Theranostics Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)
Yahoo - 2026-09-18
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
Benzinga - 2026-09-18
Dated September 17, CHMP Recommends EU Label Expansion For Novartis' Cosentyx In Polymyalgia Rheumatica After Inadequate Glucocorticoid Response Or Relapse During Taper
SeekingAlpha - 2026-09-18
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Yahoo - 2026-09-17
Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years
Yahoo - 2026-09-17
A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too
Yahoo - 2026-09-17
Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
Benzinga - 2026-09-17
Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform
Yahoo - 2026-09-17
RAMSAY SANTE Group unveils "Connecting Care 2030"
Yahoo - 2026-09-16
TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry
Yahoo - 2026-09-16
Critics Warn of AI-Driven Disaster. Anthropic and Novo Are Betting on the Opposite.
Yahoo - 2026-09-16
Trialynx Wins Forge’s DPHARM Idol Disrupt 2026
Yahoo - 2026-09-16
Novartis to pay $125M for blood-brain barrier crossing platform
Yahoo - 2026-09-16
Changes in the Suominen Leadership Team
Yahoo - 2026-09-16
AstraZeneca shares oversold after trial flops and merger talk, says UBS
Benzinga - 2026-09-16
'Novartis Experimental Drug for ALS Fails in Another Pipeline Hit' - Bloomberg
Yahoo - 2026-09-16
Sironax Announces Option Exercise and Asset Purchase
Yahoo - 2026-09-16
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Yahoo - 2026-09-15
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
Yahoo - 2026-09-15
FDA clears first generic radioligand drug; Sionna turns to layoffs
Yahoo - 2026-09-15
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Yahoo - 2026-09-15
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
Yahoo - 2026-09-15
Legend Naming Novartis Executive as CEO
Yahoo - 2026-09-14
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Yahoo - 2026-09-14
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
Yahoo - 2026-09-14
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
Yahoo - 2026-09-14
Palantir's AIPCon Highlights Data Sovereignty Demand, Ecosystem Adoption, Oppenheimer Says
Yahoo - 2026-09-14
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Yahoo - 2026-09-13
Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.
Yahoo - 2026-09-13
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone
Yahoo - 2026-09-12
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
Yahoo - 2026-09-11
Novartis: More Pain on the Way?
Yahoo - 2026-09-11
Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN)
Yahoo - 2026-09-11
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Yahoo - 2026-09-11
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
Yahoo - 2026-09-11
Amgen Drops 10% on a Trial It Didn't Even Run
Yahoo - 2026-09-11
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
Yahoo - 2026-09-11
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
Yahoo - 2026-09-11
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks
Yahoo - 2026-09-11
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
Yahoo - 2026-09-10
BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)
Yahoo - 2026-09-10
High Co (STU:HIH) (H1 2026) Earnings Call Highlights: Strong Organic Growth and Strategic ...
Yahoo - 2026-09-10
Could Remibrutinib Become the Next $9 Billion Drug for Novartis?
Yahoo - 2026-09-10
Novartis stock in hot water after another key failure
Yahoo - 2026-09-10
Sector Update: Healthcare Stocks Softer Late Afternoon
Yahoo - 2026-09-10
Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
Yahoo - 2026-09-10
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
Yahoo - 2026-09-10
NVS Stock On Track For Worst Week In Over 7 Years After Two Trial Failures In A Week — Investor Reportedly Seeks Board Overhaul
Yahoo - 2026-09-10
Sector Update: Healthcare Stocks Softer in Afternoon Trading
Yahoo - 2026-09-10
Tecan to participate in upcoming Investor Conference
SeekingAlpha - 2026-09-10
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
Yahoo - 2026-09-10
Update: Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures
Yahoo - 2026-09-10
Artisan Partners calls for Novartis board changes amid trial, acquisition failures
Benzinga - 2026-09-10
HSBC Upgrades Novartis to Hold, Raises Price Target to $136
Yahoo - 2026-09-10
CapMan acquires Hotel Crowne Plaza Copenhagen in Denmark
Yahoo - 2026-09-10
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
Benzinga - 2026-09-10
Nvidia, FAA Join Palantir’s AI Expansion as Cyber Push Takes Off
Yahoo - 2026-09-09
Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?
Yahoo - 2026-09-09
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Yahoo - 2026-09-09
HighCo: Half-Year 2026 Results
Yahoo - 2026-09-09
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
Yahoo - 2026-09-09
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Yahoo - 2026-09-09
Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls
Yahoo - 2026-09-09
Company News for Sep 9, 2026
Yahoo - 2026-09-09
Giovanni Caforio Appointed Operating Advisor to CD&R Funds
SeekingAlpha - 2026-09-09
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Yahoo - 2026-09-08
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons
Yahoo - 2026-09-08
Stock Market Today: Dow Dives, Oil Spikes After Saudi Attacks; Amgen Swoons On These Results (Live Coverage)
Yahoo - 2026-09-08
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Yahoo - 2026-09-08
Novartis Stock Tanks Following Third Major Pipeline Setback
Yahoo - 2026-09-08
AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market
Yahoo - 2026-09-08
NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
Yahoo - 2026-09-08
Sector Update: Healthcare Stocks Fall Late Afternoon
Yahoo - 2026-09-08
Sector Update: Healthcare Stocks Fall Tuesday Afternoon
Yahoo - 2026-09-08
Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says
Yahoo - 2026-09-08
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Yahoo - 2026-09-08
Novartis Crashes 13.5% After $12 Billion Deal's Lead Drug Fails
Yahoo - 2026-09-08
Novartis Trial Failure Sparks Biopharma Options Frenzy
Yahoo - 2026-09-08
European Stocks Close Mixed in Tuesday Trading; Oil Prices Surge As Middle East Fighting Worsens
Yahoo - 2026-09-08
Novartis’s Pipeline Just Lost Two Big Bets
SeekingAlpha - 2026-09-08
Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)
Benzinga - 2026-09-08
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Benzinga - 2026-09-08
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Benzinga - 2026-09-08
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
Benzinga - 2026-09-08
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
Benzinga - 2026-09-08
What's Going On With Amgen Stock Tuesday?
Benzinga - 2026-09-08
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
Benzinga - 2026-09-08
Why Is Eli Lilly Stock Falling Tuesday?
SeekingAlpha - 2026-09-08
NewAmsterdam Pharma: Potential Coupled With Uncertainty
SeekingAlpha - 2026-09-08
Novartis: 2 Significant Pipeline Setbacks Can Be Absorbed
Yahoo - 2026-09-08
Novartis India acquires Pfizer brands for $132m
Benzinga - 2026-09-08
Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)
Benzinga - 2026-09-08
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga - 2026-09-08
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Benzinga - 2026-09-08
Market-Moving News for September 8th
Yahoo - 2026-09-08
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Benzinga - 2026-09-08
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Benzinga - 2026-09-07
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday
Yahoo - 2026-09-07
Amgen's 7,297-Patient Heart Bet Just Inherited a Higher Bar
Yahoo - 2026-09-07
Novartis (NVS) Has a Potential $3 Billion MS Opportunity — But Investors Face Key Risks
Yahoo - 2026-09-07
Novartis Falls 1.9% as Pelacarsen Failure Erases CHF4.9 Billion
Yahoo - 2026-09-07
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Yahoo - 2026-09-07
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
Yahoo - 2026-09-07
Novartis Just Lost a Potential $6 Billion Drug Opportunity
Benzinga - 2026-09-07
Brent Jumps to $97, German AfD Party Wins Big: Stock Market Today
Yahoo - 2026-09-07
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah
Yahoo - 2026-09-07
Novartis Shares Fall After Pelacarsen Misses Primary Goal in Late-Stage Heart Trial
Yahoo - 2026-09-07
Weight loss is just the beginning of GLP-1's: Novo Nordisk CEO
Benzinga - 2026-09-07
Reported Earlier, Royalty Pharma Prices $2B Senior Unsecured Notes Offering With $600M Due 2031 At 4.450%, $900M Due 2035 At 5.200%, And $500M Due 2055 At 5.950%
Yahoo - 2026-09-05
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Yahoo - 2026-09-04
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
Yahoo - 2026-09-04
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Yahoo - 2026-09-04
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
Yahoo - 2026-09-04
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Yahoo - 2026-09-04
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Benzinga - 2026-09-04
Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events
SeekingAlpha - 2026-09-04